株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

個別化医療の世界市場

Personalized Medicines

発行 Global Industry Analysts, Inc. 商品コード 301518
出版日 ページ情報 英文 285 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
個別化医療の世界市場 Personalized Medicines
出版日: 2014年03月01日 ページ情報: 英文 285 Pages
概要

当レポートでは、世界の個別化医療市場について調査し、地域別の包括的動向、2011〜2020年の予測、参入企業のプロファイルをまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 概要
    • 途上国が成長を牽引
    • 個別化医療は緩やかに成長
    • 個別化医療と患者ケアに及ぼす影響
    • 個別化医療の登場はブロックバスターの終焉の兆しなのか
    • 認可済み個別化医療リスト
  • 市場成長促進因子と阻害因子
  • 個別化医療:市場動向と課題
  • 腫瘍学:主要な個別化医療市場
    • 主要市場
    • 癌の診断件数の増加
    • 世界の癌統計:発症率と死亡率データ
    • 年齢別癌になりやすい部位
    • 途上国の癌発症件数の増加が個別化医療市場に好影響
    • 癌治療のための個別化委薬剤の重要性増大
    • 世界の癌バイオマーカー市場の成長
    • FDAが認可した疾患別予防的バイオマーカー
    • 癌治療における個別化医療の導入に関する課題
  • 技術的進歩
  • 製品概要
  • 製品イントロダクションと認可
  • 近年の業界の動き
  • 主要企業
    • Abbott Molecular, Inc.
    • Affymetrix, Inc.
    • AstraZeneca plc
    • Bayer HealthCare Pharmaceuticals
    • Beckman Coulter Genomics
    • bioMerieux SA
    • Clarient, Inc.
    • Dako Denmark A/S
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc.
    • Hologic, Inc.
    • IRIS Personalized Medicine
    • Lab 21 Limited
    • Macrogen, Inc.
    • QIAGEN NV
    • Rosetta Genomics Ltd
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他
目次
Product Code: MCP-7877

This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Product Segments: Targeted Therapeutics, and Tests & Lab Services. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 85 companies including many key and niche players such as -

Abbott Molecular, Inc.
Affymetrix, Inc.
AstraZeneca plc
Bayer HealthCare Pharmaceuticals
Beckman Coulter Genomics

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Personalized Medicine

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Prelude
  • Developing Countries Drive Growth
  • Personalized Medicines Slowly Gaining Ground
  • Personalized Medicine and Its Impact on Patient Care
    • Table 1: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart)
  • Is Emergence of Personalized Medicine Signaling the End of Blockbusters?
  • List of Select Approved Personalized Medicines

2. MARKET GROWTH DRIVERS AND RESTRAINTS

  • Growth Drivers in a Gist
  • Key Market Restraints
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
  • Ballooning Global Population Offers Significant Growth Opportunities
    • Table 2: Top 25 Countries Worldwide in Terms of Population: 2010 & 2013 (includes corresponding Graph/Chart)
  • Aging Global Population Drives Personalized Medicines
    • Table 3: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 4: Over-65 Years Population as a % of Total Population (2010 & 2020P) (includes corresponding Graph/Chart)
    • Table 5: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
    • Table 6: Life Expectancy at Birth for Select Countries (2012) (includes corresponding Graph/Chart)
    • Table 7: Percentage of Population Aged 65 and Above in EU-27 Countries, the US and Japan (1960-2030) (includes corresponding Graph/Chart)
    • Table 8: Life Expectancy Rates at Birth by Geographic Region (1990 & 2011) (includes corresponding Graph/Chart)
  • Increasing Healthcare Spending in Emerging Markets
    • Table 9: Healthcare Spending as % of GDP in Select Countries (2011) (includes corresponding Graph/Chart)
  • Technological Advancements and Consumer Push to Drive Personalized Medicine
  • Economic Uncertainty Affects Spending on Healthcare Services

3. PERSONALIZED MEDICINE - MARKET TRENDS & CHALLENGES

  • Changing Patients' Trends Drive Personalized Medicine
  • Adverse Drug Reactions of Prescription Drugs Drive Personalized Medicine Market
  • List of Top 10 Drugs with Adverse Drug Reactions
  • Genomics to Dictate Advancement of Personalized Medicines
  • Investors' Interest Personalized Medicines Gathers Steam
  • Differentiation - The Key Aspect of Personalized Medicines to Draw Investors
  • Growing Investments in Sequencing Segment Drives Personalized Medicines Market
  • Companion Diagnostics Make Way for Personalized Medicine
  • Select Popular Drugs with Companion Diagnostics
  • Biomarkers as Companion Diagnostics
  • Personalized Medicines Helps Reducing R&D Costs
  • Personalized Medicine - A Corporate Growth Strategy
  • Development Pipeline Reveals Promising Picture for Personalized Medicine
  • Advancements in Biomedical Imaging to Enhance Personalized Medicines
  • Increasing Use of Personalized Medicines Drives Genetic Testing
  • Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
  • Next-Generation Sequencing - A Giant Leap in Genome Sequencing
  • Single Nucleotide Polymorphism (SNP) - Making Advancements in Personalized Medicine
  • Personalized Medicine Industry - Inundated with Data
  • Challenges for Personalized Medicine
  • Lack of Clinically Useful Diagnostic Tests - Growth Dampener
  • Economics of Personalized Medicine
  • Adoption of Personalized Medicines - A Peek into Developed and Developing Economies
  • Personalized Medicines Trigger Competition in the Market

4. ONCOLOGY: A MAJOR PERSONALIZED MEDICINE MARKET

  • Oncology - A Key Market for Personalized Medicine
  • Diagnosed Cases of Cancer on the Rise
    • Table 10: Global Cancer Incidence by Region: 2012 (includes corresponding Graph/Chart)
    • Table 11: Cancer Incidence in Developed Nations by Site: 2012 (includes corresponding Graph/Chart)
  • World Cancer Statistics: Incidence and Mortality Data
    • Table 12: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 13: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 14: New Cancer Cases in the World by Affected Site (2012) (In Thousands) (includes corresponding Graph/Chart)
    • Table 15: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding Graph/Chart)
    • Table 16: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart)
    • Table 17: Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart)
    • Table 18: Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart)
  • Cancer Prone Sites based on Age
  • Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market
  • Growing Importance of Personalized Drugs for Cancer Treatment
  • Global Cancer Biomarkers Market to Exhibit Growth
  • Few FDA Approved Predictive Biomarkers by Disease Area
  • Challenges for Adoption of Personalized Medicine in Cancer Treatment

5. SELECT TECHNOLOGICAL ADVANCEMENTS

  • NanoVelcro Chip Device - Enhanced to Personalize Treatment for Prostate Cancer
  • Development of New Cancer Treatment Method for Personalized Cancer Therapy
  • Gene Therapy using a Pill for Treating Cancer
  • New Ways of Offering Personalized Cancer Treatments
  • Theranostic Imaging - Developed for Offering Personalized Cancer Medicine
  • New Personalized Treatment Approach Prolongs the Life of Lung Cancer Patients

6. PRODUCT OVERVIEW

  • Personalized Medicine
  • Benefits of Personalized Medicines
  • Few Applications of Personalized Medicine
  • Colorectal Cancer
  • Blood Clots
  • Breast Cancer
  • Diagnostics in Personalized Medicine
  • Genetic Tests
  • Companion Diagnostics
  • Genetic Testing
  • Types of Genetic Testing
    • Prenatal Diagnosis
    • Cancer Testing
    • Carrier Identification
    • Newborn Screening
    • Predictive Testing
    • Pre-Symptomatic Testing
    • Cytogenetic Tests
    • Table 19: Costs of Select Genetic Tests
  • Proteomics: A Critical Drug Discovery Tool
  • Proteomics and Genomics: A Comparison

7. PRODUCT INTRODUCTIONS AND APPROVALS

  • NMTC Launches Expanded Personalized Medicine Panel Created on Luminex's xMAP Technology
  • Dako to Introduce New Antibody to Diagnose Breast Cancer
  • bioMerieux's New Generation VIDAS(r) 3 Obtains CE Marking
  • GSK's Two New Single-Agent Oral Oncology Treatments Receive FDA Approval
  • Dako Obtains FDA Approval for Two Companion Diagnostic Assays for Genentech's Kadcyla
  • Genentech Receives FDA Approval for Kadcyla Drug
  • Dako's FISH Assay for Cancer Diagnostics Obtains FDA Approval
  • Luminex Receives US FDA Approval for MAGPIX(r) Instrument with xTAG GPP
  • QIAGEN Obtains FDA Approval for Marketing therascreen(r) KRAS RGQ PCR Kit
  • Roche Gains Approval from EMA for PERJETA
  • OGT Unveils SureSeq(tm) Solid Tumor Panel Sequencing Service
  • Abbott Launches Hepatitis C Virus Genotyping Test
  • Luminex Obtains CE Marking for Neonatal Screening Systems
  • IRIS International Launches NADiA(r) ProsVue(tm) Prognostic Test for Cancer
  • Lab21 Launches Novel Companion Diagnostic Service for Lung Cancer
  • Lab21 to Offer FDA approved Companion Diagnostic Test
  • Rosetta Genomics Obtains Approval from New York State Department of Health for miRview(r) Lung Assay
  • Merck Serono Receives Approval for Erbitux(r) for use in Neck and Head Cancer
  • Affymetrix Obtains Approval from China's SFDA for GeneChip(r)System 3000Dx v.2
  • Dako Obtains FDA Approval for Hercep Test(tm) and HERFISH pharma Dx(tm) kit
  • Roche Obtains Approval of Perjeta(tm) by USFDA
  • NeoGenomics Introduces NeoTYPE(tm) Prognostic Panel

8. RECENT INDUSTRY ACTIVITY

  • Cancer Genetics and Mayo Clinic Establish JV
  • QIAGEN and Eli Lilly Sign Master Collaboration Agreement
  • Ignyta Takes Over Actagene Oncology
  • Lab21 Divests Laboratory Business to Reedy Acquisitions
  • Mayo Clinic Enters into Strategic Partnership with Silicon Valley Biosystems
  • Bristol Myers Squibb to Collaborate with Adaptive Biotechnologies
  • Government of Quebec Invests in Personalized Medicine Partnership for Cancer
  • Millennium Pharmaceuticals and Worldwide Innovative Network Consortium Ink Collaboration Agreement
  • Affymetrix and UK Biobank Ink Contract
  • Bayer and Seattle Genetics Enter into Novel ADC Collaboration
  • Lab21 Joins Hands with IntegraGen to Develop Novel Colorectal Cancer Diagnosis
  • Macrogen Establishes MCL
  • INVENT and Heliant Co-Invest in Sanguine BioSciences
  • Dako and Eli Lilly Enter into Partnership for Companion Diagnostic Tests Development
  • Geisinger to Enter into an Alliance with Indivumed
  • Deloitte Takes Over Recombinant Data
  • Thermo Fisher Scientific Renews Partnership with bioMerieux
  • QIAGEN Sign Agreements to Acquire Global Rights for Two Biomarkers
  • Selventa to Build Disease Models for Johnson & Johnson
  • Quintiles Takes Over Expression Analysis
  • Mckesson Acquires CDS Oncology Assets from Proventys
  • Horizon Partners with H3 Biomedicine to Develop Target Groups for Cancer Drugs
  • Abbott to Collaborate with Merck for FISH-based Diagnostic Test Evaluation
  • Bayer and QIAGEN Sign Strategic Partnership for Companion Diagnostic Tests Development
  • Life Technologies Signs a License and Supply Contract with VelaDx
  • IDBS Announces Deployment of ORIS by King's Health Partners
  • PGXL Laboratories Inks Multi-Year Distribution Partnership Agreement with Essential Molecular Testing
  • Uniquest Inks Memorandum of Understanding with Aquavit Pharmaceuticals
  • Agilent Technologies Acquires Dako
  • IRIS International Signs Merger Agreement with Danaher
  • Lab21 and BD Diagnostics Sign Collaboration Agreement
  • Lab21 Inks Partnership Agreement with a Major Pharmaceutical Company
  • Lab21 Signs Partnership Agreement with Leading IVD Company
  • Lab21 and ITOR Establish Clinical Genomics Center
  • Lab21 Takes over PCR Technology
  • PerkinElmer and Macrogen Enter into Agreement
  • NeoGenomics and Health Discovery Ink Exclusive Agreement for Global Licensing
  • QIAGEN Inks Agreement with Lepu Medical
  • QIAGEN Inks Agreement with Bio-X Center

9. FOCUS ON SELECT PLAYERS

  • Abbott Molecular, Inc. (US)
  • Affymetrix, Inc. (US)
  • AstraZeneca plc (UK)
  • Bayer HealthCare Pharmaceuticals (Germany)
  • Beckman Coulter Genomics (US)
  • bioMerieux SA (France)
  • Clarient, Inc. (US)
  • Dako Denmark A/S (Denmark)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc. (UK)
  • Hologic, Inc. (US)
  • IRIS Personalized Medicine (US)
  • Lab 21 Limited (UK)
  • Macrogen, Inc. (Korea)
  • QIAGEN NV (The Netherlands)
  • Rosetta Genomics Ltd (Israel)

10. GLOBAL MARKET PERSPECTIVE

    • Table 20: World Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 22: World Recent Past, Current and Future Analysis for Targeted Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 23: World 15-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 24: World Recent Past, Current and Future Analysis for Tests & Lab Services for Personalized Medicine by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 25: World 15-Year Perspective for Tests & Lab Services for Personalized Medicine by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • US Individualized Medicine Market to Witness Significant Growth
    • Companies and Investors Bullish on Personalized Medicine Market in the US
    • Government Agencies Push for Personalized Medicines
    • Personalized Medicine Regulations in the FDA - Changing for the Better
    • Challenges for FDA in Approving Personalized Drugs
    • Increasing Burden of Chronic Diseases Drives Focus onto Personalized Treatment
    • Companion Diagnostic Market in the US
      • Number of Companion Diagnostics under Development Keeps Soaring
    • Direct-to-Consumer Testing - A Growing Market
    • Cancer Statistics in the US
    • Table 26: New Cancer Cases by Gender and Affected Site in the US (2013)
    • Personalized Medicine Creating Opportunities for Diagnostics Testing Services
    • Molecular Diagnostics: Promising Growth Opportunities
    • Genetic and Genomic Clinical Lab Testing Market: Promising Prospects
    • Product Launches/ Approvals
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 27: The US Recent Past, Current and Future Analysis for Personalized Medicines by Segment -Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 28: The US 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • Rising Incidence of Chronic Diseases Spurs Need for Personalized Medicines
    • Table 29: New Cancer Cases in Canada by Gender and Affected Site (2012) (includes corresponding Graph/Chart)
    • Table 30: New Cancer Cases in Canada by Province (2012) (includes corresponding Graph/Chart)
    • Table 31: New Cancer Cases in Canada by Age Group and Gender (2012) (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 32: Canadian Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 33: Canadian 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Demographics Drive Market Growth
    • Table 34: Percentage Breakdown of Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
    • Table 35: Over 65 Years Population in Japan (1950-2010) (includes corresponding Graph/Chart)
    • Product Approval
  • B. Market Analytics
    • Table 36: Japanese Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 37: Japanese 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Debt Crisis in Europe Affects Healthcare Industry
    • European Healthcare System: In a State of Transition?
    • Aging Population to Drive Demand for Personalized Medicines
    • Table 38: Population Breakup by Age Group for Select European Countries: 2012 (As a % of Total Population) (includes corresponding Graph/Chart)
    • Insight into Molecular Diagnostics Markets in Europe
    • Table 39: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)
    • Regulatory Scenario in Europe for Companion Diagnostics
      • Companion Diagnostics: Select European Players with Strong Biomarker Pipeline
    • The Need for Improving Reimbursement Policies
    • Product Approvals/Launches
  • B. Market Analytics
    • Table 40: European Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 41: European 15-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 42: European Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 43: European 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Outlook
    • Biomerieux Sa - A Key Player
  • B. Market Analytics
    • Table 44: French Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 45: French 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Outlook
    • Market Overview
    • Strategic Corporate Development
    • Bayer Healthcare Pharmaceuticals - A Key Player
  • B. Market Analytics
    • Table 46: German Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 47: German 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 48: Italian Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 49: Italian 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Initiatives Supporting the Personalized Medicine Market
    • Product Approvals/Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 50: The UK Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 51: The UK 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • Spain - Poised to become a Reckoning Force in Personalized Medicines
    • Strategic Corporate Development
    • Select Players
  • B. Market Analytics
    • Table 52: Rest of Europe Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 53: Rest of Europe 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Healthcare Spending in Asia-Pacific: On the Rise
      • China and India: Two Fast-Growing Markets
    • Focus on Select Regions
      • India
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine in India
      • Challenges Ahead...
      • China
      • Government Support Drives Personalized Medicine Market in China
    • Product Launch
    • Strategic Corporate Developments
    • Macrogen, Inc. (Korea) - A Key Player
  • B. Market Analytics
    • Table 54: Asia-Pacific Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 55: Asia-Pacific 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Outlook
    • Rosetta Genomics Ltd (Israel) - A Key Player
  • B. Market Analytics
    • Table 56: Rest of World Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2020 (includes corresponding Graph/Chart)
    • Table 57: Rest of World 15-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2014 and 2020 (includes corresponding Graph/Chart)
Back to Top